Page last updated: 2024-10-30

metformin and Hirsutism

metformin has been researched along with Hirsutism in 78 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Hirsutism: A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.

Research Excerpts

ExcerptRelevanceReference
"Assessing the impact of adding combined oral contraceptives (COCs) or metformin to laser hair removal on the quality of life of polycystic ovarian syndrome (PCOS) patients with hirsutism."9.41Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients. ( Dorgham, D; Dorgham, N; El-Kalioby, M; Haggag, H; Sharobim, A, 2021)
" To study the combined efficacy of exercise and metformin on above parameters in women with polycystic ovary syndrome."9.30Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. ( Jain, S; Pasrija, S; Tiwari, N, 2019)
"We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)."9.24Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017)
"The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)."9.22Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016)
" It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone."9.19In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014)
"In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin."9.15Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011)
" Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1."9.15Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2011)
"To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)."9.15Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011)
" Hirsutism was significantly better controlled in the metformin group (p = 0."9.14Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. ( Adibi, N; Asilian, A; Kachuei, A; Rezvanian, H; Shojaee-Moradie, F; Siavash, M, 2009)
"To compare hormone levels and clinical outcomes in patients with polycystic ovary syndrome (PCOS) after metformin therapy or laparoscopic ovarian diathermy (LOD) at 6 months follow-up."9.14Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome. ( Asgari, Z; Ashrafinia, M; Eslami, B; Hosseini, R; Moini, A, 2009)
"The aim of this study was to evaluate the effects of metformin in addition to diet and exercise on endocrine and metabolic disturbances in women with polycystic ovary syndrome (PCOS) in a prospective, double-blind, randomized, placebo (PBO) control trial."9.14Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. ( Fux Otta, C; Gaido, MI; Iraci, GS; Kaplan, R; Torres, D; Wior, M; Wyse, EP, 2010)
"65 kg/m(2)) hirsute women with polycystic ovary syndrome and normal insulin sensitivity were treated with 850 mg metformin orally, three times daily, for 4 months."9.12Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. ( Baracat, EC; Halpern, A; Maciel, GA; Marcondes, JA; Yamashita, SA, 2007)
"Our data show that both metformin and rosiglitazone improve ovarian function and hirsutism in patients with PCOS."9.11The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Cakir, N; Karakoç, A; Tiras, B; Törüner, FB; Yilmaz, M, 2005)
" There was a significant improvement in hirsutism at the end of the metformin phase compared with placebo: F-G score 15."9.10The effect of metformin on hirsutism in polycystic ovary syndrome. ( Gordon, D; Kelly, CJ, 2002)
"Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)."8.88A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012)
"The object of this review was to compare metformin versus oral contraceptive pill (OCP) treatment in polycystic ovary syndrome."8.84Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. ( Costello, MF; Eden, J; Johnson, NP; Shrestha, B; Sjoblom, P, 2007)
"Metformin administration resulted in significant decrease in the body weight, body mass index, hirsutism score, fasting and postprandial blood glucose, fasting serum insulin, HOMA index, sleep disturbances scale, and Epworth sleepiness scale compared to the untreated PCOS group."7.80Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. ( Abdelmotaleb, GS; Aly, MK; El-Sharkawy, AA; Kabel, AM, 2014)
"Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome."7.78Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012)
"Treatment with metformin three times 500 mg daily had been advised since 2002, to patients suffering from the polycystic ovary syndrome diagnosed by the Rotterdam criteria and who did not want to take contraceptive pills."7.77[Metformin treatment with or without life style changes in patients with polycystic ovary syndrome]. ( Petrányi, G; Zaoura-Petrányi, M, 2011)
"This study evaluated the use of metformin as first line treatment for patients with polycystic ovary syndrome."7.74The use of metformin as first line treatment in polycystic ovary syndrome. ( Abbas, M; Gannon, M, 2008)
"Based on the favourable international experience with metformin in the most common female endocrine disease, the polycystic ovary syndrome, which has insulin resistance in the background, the author's treatment advice has been this in such cases since early 2002: for sexually active women who do not want to become pregnant for the time being, anti-androgenic contraceptive pill; for those who do not want to take contraceptives, contraceptives are contraindicated, or who do want to conceive, metformin."7.73[Treatment experience with metformin in polycystic ovary syndrome]. ( Petrányi, G, 2005)
"Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well."7.73The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005)
"Hirsutism is a common and distressing symptom frequently encountered in women with polycystic ovary syndrome (PCOS), who also show relative insulin resistance."6.71Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. ( Fleming, R; Harborne, L; Lyall, H; Norman, J; Sattar, N, 2003)
"Metformin was then given at a dose of 500 mg three times a day for 8 weeks, after which time the pretreatment study was repeated."6.71Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. ( Dehghan-Kooshkghazi, M; Kazerooni, T, 2003)
"Metformin and OCPs were similar in terms of impact on hirsutism."6.53Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Florez, ID; Thabane, L, 2016)
"Assessing the impact of adding combined oral contraceptives (COCs) or metformin to laser hair removal on the quality of life of polycystic ovarian syndrome (PCOS) patients with hirsutism."5.41Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients. ( Dorgham, D; Dorgham, N; El-Kalioby, M; Haggag, H; Sharobim, A, 2021)
" To study the combined efficacy of exercise and metformin on above parameters in women with polycystic ovary syndrome."5.30Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. ( Jain, S; Pasrija, S; Tiwari, N, 2019)
"We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)."5.24Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017)
" Additionally, novel cosmetic techniques like electrolysis, laser and use of topically applied eflornithine to tackle the most distressing feature of facial hirsutism associated with PCOS, non-pharmacological therapy like acupuncture and the role of herbal medicine in PCOS management have also been discussed."5.22Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. ( Ali, T; Amin, F; Ara, R; Bader, GN; Kareem, O; Malik, A; Mir, SA; Rashid, R, 2022)
"The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)."5.22Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016)
" It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone."5.19In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014)
" They were treated with clomiphene citrate, metformin, or both (combination) for up to six cycles, and hirsutism evaluators were blinded to group assignment."5.16Altering hirsutism through ovulation induction in women with polycystic ovary syndrome. ( Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Gosman, GG; Huang, H; Legro, RS; McGovern, PG; Myers, ER; Nestler, JE; Roth, LW; Schlaff, WD; Steinkampf, MP; Zhang, H, 2012)
" Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1."5.15Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2011)
"To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)."5.15Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011)
"In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin."5.15Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011)
"To compare hormone levels and clinical outcomes in patients with polycystic ovary syndrome (PCOS) after metformin therapy or laparoscopic ovarian diathermy (LOD) at 6 months follow-up."5.14Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome. ( Asgari, Z; Ashrafinia, M; Eslami, B; Hosseini, R; Moini, A, 2009)
" Hirsutism was significantly better controlled in the metformin group (p = 0."5.14Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. ( Adibi, N; Asilian, A; Kachuei, A; Rezvanian, H; Shojaee-Moradie, F; Siavash, M, 2009)
"The aim of this study was to evaluate the effects of metformin in addition to diet and exercise on endocrine and metabolic disturbances in women with polycystic ovary syndrome (PCOS) in a prospective, double-blind, randomized, placebo (PBO) control trial."5.14Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. ( Fux Otta, C; Gaido, MI; Iraci, GS; Kaplan, R; Torres, D; Wior, M; Wyse, EP, 2010)
"65 kg/m(2)) hirsute women with polycystic ovary syndrome and normal insulin sensitivity were treated with 850 mg metformin orally, three times daily, for 4 months."5.12Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. ( Baracat, EC; Halpern, A; Maciel, GA; Marcondes, JA; Yamashita, SA, 2007)
"Our data show that both metformin and rosiglitazone improve ovarian function and hirsutism in patients with PCOS."5.11The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Cakir, N; Karakoç, A; Tiras, B; Törüner, FB; Yilmaz, M, 2005)
" There was a significant improvement in hirsutism at the end of the metformin phase compared with placebo: F-G score 15."5.10The effect of metformin on hirsutism in polycystic ovary syndrome. ( Gordon, D; Kelly, CJ, 2002)
"Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)."4.88A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012)
"In this systematic review we present information relating to the effectiveness and safety of the following interventions: finasteride, flutamide, metformin, spironolactone, cyproterone acetate-ethinylestradiol (co-cyprindiol), interventions to achieve weight loss, ketoconazole, and mechanical hair removal."4.85PCOS. ( Cahill, D, 2009)
"The object of this review was to compare metformin versus oral contraceptive pill (OCP) treatment in polycystic ovary syndrome."4.84Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. ( Costello, MF; Eden, J; Johnson, NP; Shrestha, B; Sjoblom, P, 2007)
" A significant reduction in hirsutism was found for flutamide, spironolactone, cyproterone acetate combined with an oral contraceptive, thiazolidinediones, oral contraceptive pills (OCPs), finasteride and metformin but not for placebo."4.84A systematic review of commonly used medical treatments for hirsutism in women. ( Conway, GS; Koulouri, O, 2008)
" When compared with metformin, spironolactone reduced hirsutism scores by 1."4.84Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. ( Cosma, M; Erwin, PJ; Flynn, DN; Kurtz, DM; Labella, ML; Montori, VM; Mullan, RJ; Swiglo, BA, 2008)
"Our objective was to conduct a systematic review and metaanalyses of randomized controlled trials of metformin or TZDs for the treatment of hirsutism."4.84Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. ( Cosma, M; Elamin, MB; Erwin, PJ; Flynn, DN; Kurtz, DM; Labella, ML; Montori, VM; Mullan, RJ; Swiglo, BA, 2008)
"Metformin administration resulted in significant decrease in the body weight, body mass index, hirsutism score, fasting and postprandial blood glucose, fasting serum insulin, HOMA index, sleep disturbances scale, and Epworth sleepiness scale compared to the untreated PCOS group."3.80Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. ( Abdelmotaleb, GS; Aly, MK; El-Sharkawy, AA; Kabel, AM, 2014)
"Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome."3.78Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012)
"Treatment with metformin three times 500 mg daily had been advised since 2002, to patients suffering from the polycystic ovary syndrome diagnosed by the Rotterdam criteria and who did not want to take contraceptive pills."3.77[Metformin treatment with or without life style changes in patients with polycystic ovary syndrome]. ( Petrányi, G; Zaoura-Petrányi, M, 2011)
"This study evaluated the use of metformin as first line treatment for patients with polycystic ovary syndrome."3.74The use of metformin as first line treatment in polycystic ovary syndrome. ( Abbas, M; Gannon, M, 2008)
"Based on the favourable international experience with metformin in the most common female endocrine disease, the polycystic ovary syndrome, which has insulin resistance in the background, the author's treatment advice has been this in such cases since early 2002: for sexually active women who do not want to become pregnant for the time being, anti-androgenic contraceptive pill; for those who do not want to take contraceptives, contraceptives are contraindicated, or who do want to conceive, metformin."3.73[Treatment experience with metformin in polycystic ovary syndrome]. ( Petrányi, G, 2005)
"Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well."3.73The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005)
"Metformin was then given at a dose of 500 mg three times a day for 8 weeks, after which time the pretreatment study was repeated."2.71Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. ( Dehghan-Kooshkghazi, M; Kazerooni, T, 2003)
"Hirsutism is a common and distressing symptom frequently encountered in women with polycystic ovary syndrome (PCOS), who also show relative insulin resistance."2.71Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. ( Fleming, R; Harborne, L; Lyall, H; Norman, J; Sattar, N, 2003)
"Metformin treatment was well tolerated and was accompanied by a marked drop in hirsutism score, insulin response to oral glucose tolerance test, free androgen index, and baseline testosterone, androstenedione, dehydroepiandrosterone, and dehydroepiandrosterone sulfate levels (all P < 0."2.69Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. ( de Zegher, F; Ibáñez, L; Marcos, MV; Potau, N; Valls, C, 2000)
"Metformin and OCPs were similar in terms of impact on hirsutism."2.53Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Florez, ID; Thabane, L, 2016)
"Hirsutism affects 5-25% women, and the condition is most often caused by polycystic ovary syndrome (PCOS)."2.53Endocrine and metabolic characteristics in polycystic ovary syndrome. ( Glintborg, D, 2016)
"Polycystic ovary syndrome is the most common hormonal and metabolic disorder likely to affect women."2.52[Prevention and treatment of the complications of polycystic ovarian syndrome--the significance of evidence-based, interdisciplinary management]. ( Csenteri, OK; Gődény, S, 2015)
"Polycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women."2.52[Evidence-based therapy of polycystic ovarian syndrome]. ( Csenteri, OK; Gődény, S, 2015)
"Hirsutism is a common medical complaint among women of reproductive age, and it affects the majority of women with the polycystic ovary syndrome (PCOS)."2.50Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. ( Gambineri, A; Pasquali, R, 2014)
"Hirsutism is defined as excess hair growth in androgen-dependent areas of the body in women."2.46Hirsutism: Diagnosis and management. ( Brodell, LA; Mercurio, MG, 2010)
"Metformin was less effective than the OCP in improving menstrual pattern (Peto odds ratio (OR) 0."2.44Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. ( Costello, M; Eden, J; Johnson, N; Shrestha, B; Sjoblom, P, 2007)
"Polycystic ovary syndrome is a multi-system endocrinopathy with long-term metabolic and cardiovascular health consequences."2.43Contemporary medical therapy for polycystic ovary syndrome. ( Domino, SE; Lanham, MS; Lebovic, DI, 2006)
"Hirsutism is the presence of excessive body hair in a male pattern distribution in a woman, and can affect up to 20% of women."1.91An evaluation of the available pharmacotherapy for the treatment of hirsutism. ( Asfour, L; Kazmi, A; Sinclair, R, 2023)
"Hirsutism is the manifestation of hyperandrogenemia in PCOS."1.32The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004)

Research

Studies (78)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (1.28)18.2507
2000's30 (38.46)29.6817
2010's40 (51.28)24.3611
2020's7 (8.97)2.80

Authors

AuthorsStudies
Rashid, R1
Mir, SA1
Kareem, O1
Ali, T1
Ara, R1
Malik, A1
Amin, F1
Bader, GN1
Cui, YY1
Jiajue, JRZ1
Chen, MP1
Lu, L1
Yu, M1
Wang, LJ1
Asfour, L1
Kazmi, A1
Sinclair, R1
Xiong, T1
Fraison, E1
Kolibianaki, E1
Costello, MF2
Venetis, C1
Kostova, EB1
Tang, Z1
Guan, J1
Mao, JH1
Han, L1
Zhang, JJ1
Chen, R1
Jiao, Z1
Dorgham, N1
Sharobim, A1
Haggag, H1
El-Kalioby, M1
Dorgham, D1
Torres-Zegarra, C1
Sundararajan, D1
Benson, J1
Seagle, H1
Witten, M1
Walders-Abramson, N1
Simon, SL1
Huguelet, P1
Nokoff, NJ1
Cree-Green, M1
Ibáñez, L6
Del Río, L1
Díaz, M3
Sebastiani, G1
Pozo, ÓJ1
López-Bermejo, A3
de Zegher, F6
Morgante, G1
Massaro, MG1
Di Sabatino, A1
Cappelli, V1
De Leo, V1
Alpañés, M1
Álvarez-Blasco, F1
Fernández-Durán, E1
Luque-Ramírez, M1
Escobar-Morreale, HF2
Lepine, S1
Jo, J1
Metwally, M1
Cheong, YC1
Tiwari, N1
Pasrija, S1
Jain, S1
Mazza, A1
Fruci, B1
Guzzi, P1
D'Orrico, B1
Malaguarnera, R1
Veltri, P1
Fava, A1
Belfiore, A1
Pasquali, R2
Gambineri, A2
Gómez-Pérez, AM1
Fernández-García, JC1
Mancha Doblas, I1
Tinahones, FJ1
Ong, KK1
Dunger, DB2
Conway, G1
Dewailly, D2
Diamanti-Kandarakis, E2
Franks, S1
Kelestimur, F3
Macut, D1
Micic, D1
Pfeifer, M1
Pignatelli, D1
Pugeat, M2
Yildiz, B1
El-Sharkawy, AA1
Abdelmotaleb, GS1
Aly, MK1
Kabel, AM1
Buzney, E1
Sheu, J1
Buzney, C1
Reynolds, RV1
Powers, SE1
Uliassi, NW1
Sullivan, SD1
Tuchman, LK1
Mehra, R1
Gomez-Lobo, V1
Spritzer, PM2
Motta, AB2
Sir-Petermann, T1
van Zuuren, EJ1
Fedorowicz, Z1
Carter, B1
Pandis, N1
Hecht Baldauff, N1
Arslanian, S1
Diri, H1
Karaburgu, S1
Acmaz, B1
Unluhizarci, K1
Tanriverdi, F1
Karaca, Z1
Goodman, NF1
Cobin, RH1
Futterweit, W1
Glueck, JS1
Legro, RS2
Carmina, E1
Gallego-Escuredo, JM1
Villarroya, F1
Gődény, S2
Csenteri, OK2
Naderpoor, N1
Shorakae, S1
de Courten, B1
Misso, ML1
Moran, LJ1
Teede, HJ1
Martins, WP1
Glintborg, D1
Al Khalifah, RA1
Florez, ID1
Dennis, B1
Thabane, L1
Bassilious, E1
Kępczyńska-Nyk, A1
Muszel, M1
Radziszewski, M1
Wocial, K1
Rezvanian, H1
Adibi, N1
Siavash, M1
Kachuei, A1
Shojaee-Moradie, F1
Asilian, A1
Cahill, D1
Ashrafinia, M1
Hosseini, R1
Moini, A1
Eslami, B1
Asgari, Z1
Klein, F1
Fux Otta, C1
Wior, M1
Iraci, GS1
Kaplan, R1
Torres, D1
Gaido, MI1
Wyse, EP1
Artini, PG1
Di Berardino, OM1
Simi, G1
Papini, F1
Ruggiero, M1
Monteleone, P1
Cela, V1
Langmár, Z1
Brodell, LA1
Mercurio, MG1
Petrányi, G2
Zaoura-Petrányi, M1
Marcos, MV2
Oner, G1
Muderris, II1
Banaszewska, B1
Pawelczyk, L1
Spaczynski, RZ1
Duleba, AJ1
Raval, AD1
Hunter, T1
Stuckey, B1
Hart, RJ1
Du, Q1
Wang, YJ1
Yang, S1
Wu, B1
Han, P1
Zhao, YY1
Kulshreshtha, B1
Gupta, N1
Ganie, MA1
Ammini, AC1
Roth, LW1
Huang, H1
Diamond, MP1
Coutifaris, C1
Carson, SA1
Steinkampf, MP1
Carr, BR1
McGovern, PG1
Cataldo, NA1
Gosman, GG1
Nestler, JE1
Myers, ER1
Zhang, H1
Schlaff, WD1
Kelly, CJ1
Gordon, D1
Awartani, KA1
Cheung, AP1
Quint, EH1
Kazerooni, T1
Dehghan-Kooshkghazi, M1
Harborne, L1
Fleming, R1
Lyall, H1
Sattar, N1
Norman, J1
Frank-Raue, K1
Schulze, E1
Ajossa, S1
Guerriero, S1
Paoletti, AM1
Orrù, M1
Melis, GB1
Barbieri, RL1
Gargiulo, AR1
Sahin, Y1
Ehrmann, DA1
Al-Inany, H1
Yilmaz, M2
Karakoç, A2
Törüner, FB1
Cakir, N2
Tiras, B2
Ayvaz, G2
Arslan, M2
Biri, A1
Törüner, F1
Bingöl, B1
Lanham, MS1
Lebovic, DI1
Domino, SE1
Costello, M1
Shrestha, B2
Eden, J2
Sjoblom, P2
Johnson, N1
Johnson, NP1
Marcondes, JA1
Yamashita, SA1
Maciel, GA1
Baracat, EC1
Halpern, A1
Homburg, R1
Koulouri, O1
Conway, GS1
Swiglo, BA2
Cosma, M2
Flynn, DN2
Kurtz, DM2
Labella, ML2
Mullan, RJ2
Erwin, PJ2
Montori, VM2
Elamin, MB1
Abbas, M1
Gannon, M1
Crave, JC1
Fimbel, S1
Lejeune, H1
Cugnardey, N1
Déchaud, H1
Valls, C1
Potau, N1
Laboureau-Soares Barbosa, S1
Rodien, P1
Rohmer, V1

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study[NCT01526616]56 participants (Actual)Interventional2010-05-31Completed
Gender Affirmative Treatment of Hypertrichosis With Intense Pulsed Light - Effect on Hair Reduction and Quality of Life[NCT05775328]39 participants (Anticipated)Observational2023-12-01Not yet recruiting
Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679]Phase 430 participants (Actual)Interventional2003-01-31Completed
A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828]Phase 3164 participants (Actual)Interventional2013-09-30Completed
Effect of Simvastatin and Metformin on Clinical, Endocrine, Metabolic and Endothelial Function of Women With Polycystic Ovary Syndrome: Prospective Randomised Trial[NCT00396513]0 participants Interventional2005-09-30Recruiting
Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome[NCT00068861]Phase 3678 participants Interventional2002-11-30Completed
Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615]80 participants (Anticipated)Observational2007-12-31Recruiting
Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488]Phase 450 participants (Actual)Interventional2013-09-30Completed
Anxiety and Sexual Malfunction in Infertile Polycystic Ovarian Syndrome Patients[NCT05056272]128 participants (Anticipated)Observational2022-01-01Recruiting
The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.[NCT03362918]60 participants (Actual)Interventional2018-01-01Completed
Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)[NCT01745471]36 participants (Anticipated)Observational2012-12-06Active, not recruiting
The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873]Phase 442 participants (Anticipated)Interventional2012-04-30Recruiting
Pilot Study on the Effects of Fasting Mimicking Diet (FMD) in Women With Polycystic[NCT05196568]100 participants (Anticipated)Interventional2021-07-01Active, not recruiting
Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898]Phase 2388 participants (Anticipated)Interventional2015-11-30Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Body Composition

Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks

Interventionpercentage of change (Mean)
Metformin-0
Oral Placebo1

Change in Body Mass Index (BMI)

(NCT01881828)
Timeframe: 0-26 weeks

Interventionpercentile (Mean)
Metformin-1
Oral Placebo1

Change in Total Daily Dose of Insulin (TDI) Per kg

(NCT01881828)
Timeframe: 0-26 weeks

Interventioninsulin per kg (Mean)
Metformin-0.1
Oral Placebo-0.0

Change in Waist Circumference

(NCT01881828)
Timeframe: 0-26 weeks

Interventioncentimeters (Mean)
Metformin-0
Oral Placebo1

Change in Blood Pressure

(NCT01881828)
Timeframe: 0-26 weeks

,
Interventionmm Hg (Mean)
Change in SystolicChange in Diastolic
Metformin00
Oral Placebo-00

Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.

Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks

,
Interventionpercentage (Mean)
HbA1cChange from Baseline to 26 Weeks
Metformin9.00.2
Oral Placebo8.90.2

Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.

Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks

,
Interventionpercentage of participants (Number)
HbA1c Decrease ≥0.5%HbA1c Increase ≥0.5%HbA1c <7.5%
Metformin19443
Oral Placebo18354

Change in Serum Lipids

(NCT01881828)
Timeframe: 0-26 weeks

,
Interventionmg/dL (Mean)
Change in LDLChange in VLDLChange in HDLChange in TriglyceridesChange in Total Cholesterol
Metformin-6-0-04-5
Oral Placebo21-163

Reviews

33 reviews available for metformin and Hirsutism

ArticleYear
Polycystic ovarian syndrome-current pharmacotherapy and clinical implications.
    Taiwanese journal of obstetrics & gynecology, 2022, Volume: 61, Issue:1

    Topics: Acupuncture; Anovulation; Eflornithine; Female; Herbal Medicine; Hirsutism; Humans; Hydroxymethylglu

2022
Statins for women with polycystic ovary syndrome not actively trying to conceive.
    The Cochrane database of systematic reviews, 2023, 07-18, Volume: 7

    Topics: Acne Vulgaris; Contraceptives, Oral; Female; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase

2023
Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: A model-based meta-analysis.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Nov-01, Volume: 190

    Topics: Androgen Antagonists; Androgens; Contraceptives, Oral; Female; Hirsutism; Humans; Hypoglycemic Agent

2023
Therapeutic approach for metabolic disorders and infertility in women with PCOS.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2018, Volume: 34, Issue:1

    Topics: Androgen Antagonists; Anovulation; Clomiphene; Contraceptives, Oral, Hormonal; Female; Gonadotropins

2018
Ovarian surgery for symptom relief in women with polycystic ovary syndrome.
    The Cochrane database of systematic reviews, 2017, 11-10, Volume: 11

    Topics: Acne Vulgaris; Clomiphene; Female; Gonadotropins; Hirsutism; Humans; Laparoscopy; Letrozole; Menstru

2017
Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome.
    European journal of endocrinology, 2014, Volume: 170, Issue:2

    Topics: Androgen Antagonists; Androgens; Bariatric Surgery; Female; Hair Removal; Hirsutism; Humans; Metform

2014
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
    Journal of the American Academy of Dermatology, 2014, Volume: 71, Issue:5

    Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, C

2014
Novel strategies in the management of polycystic ovary syndrome.
    Minerva endocrinologica, 2015, Volume: 40, Issue:3

    Topics: Adult; Clomiphene; Contraceptives, Oral, Combined; Female; Fertility Agents, Female; Fertilization i

2015
Interventions for hirsutism (excluding laser and photoepilation therapy alone).
    The Cochrane database of systematic reviews, 2015, Apr-28, Issue:4

    Topics: 5-alpha Reductase Inhibitors; Adult; Androgen Antagonists; Body Mass Index; Contraceptive Agents, Fe

2015
Optimal management of polycystic ovary syndrome in adolescence.
    Archives of disease in childhood, 2015, Volume: 100, Issue:11

    Topics: Adolescent; Contraceptives, Oral, Hormonal; Diagnosis, Differential; Disease Management; Female; Hir

2015
Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment.
    International journal of clinical practice, 2015, Volume: 69, Issue:11

    Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Female; Hirsutism; Hormones; Humans; Hyperan

2015
[Evidence-based therapy of polycystic ovarian syndrome].
    Orvosi hetilap, 2015, Nov-08, Volume: 156, Issue:45

    Topics: Amenorrhea; Androgen Antagonists; Anovulation; Anti-Obesity Agents; Chorionic Gonadotropin; Contrace

2015
[Prevention and treatment of the complications of polycystic ovarian syndrome--the significance of evidence-based, interdisciplinary management].
    Orvosi hetilap, 2015, Dec-13, Volume: 156, Issue:50

    Topics: Biomarkers; Counseling; Dermatology; Diabetes Mellitus, Type 2; Disease Management; Endocrinology; E

2015
Endocrine and metabolic characteristics in polycystic ovary syndrome.
    Danish medical journal, 2016, Volume: 63, Issue:4

    Topics: Biomarkers; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic S

2016
Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis.
    Pediatrics, 2016, Volume: 137, Issue:5

    Topics: Acne Vulgaris; Adolescent; Body Mass Index; Contraceptives, Oral; Female; Glucose Metabolism Disorde

2016
PCOS.
    BMJ clinical evidence, 2009, Jan-15, Volume: 2009

    Topics: Diabetes Mellitus, Type 2; Flutamide; Hair Removal; Hirsutism; Humans; Metformin; Polycystic Ovary S

2009
Best methods for identification and treatment of PCOS.
    Minerva ginecologica, 2010, Volume: 62, Issue:1

    Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential

2010
Hirsutism: Diagnosis and management.
    Gender medicine, 2010, Volume: 7, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Adrenal Hyperplasia, Congenital; Causality; Contraceptives, Oral; Diag

2010
Statins for women with polycystic ovary syndrome not actively trying to conceive.
    The Cochrane database of systematic reviews, 2011, Oct-05, Issue:10

    Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase

2011
A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
    Current medical research and opinion, 2012, Volume: 28, Issue:5

    Topics: Blood Glucose; Body Mass Index; Female; Hirsutism; Humans; Hyperinsulinism; Insulin Resistance; Metf

2012
Metformin and polycystic ovary syndrome: a literature review.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2002, Volume: 24, Issue:5

    Topics: Androgens; Body Mass Index; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Lipi

2002
Metformin for the treatment of the polycystic ovary syndrome.
    Minerva ginecologica, 2004, Volume: 56, Issue:1

    Topics: Adolescent; Adult; Amenorrhea; Clinical Trials as Topic; Clomiphene; Diabetes Mellitus, Type 2; Diab

2004
Medical treatment regimens of hirsutism.
    Reproductive biomedicine online, 2004, Volume: 8, Issue:5

    Topics: Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Enzyme Inhibitors; Ethinyl Estradiol;

2004
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    Clinical evidence, 2004, Issue:12

    Topics: Androgen Antagonists; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Fin

2004
Contemporary medical therapy for polycystic ovary syndrome.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2006, Volume: 95, Issue:3

    Topics: Acne Vulgaris; Adult; Clomiphene; Estrogen Antagonists; Female; Hirsutism; Humans; Hypoglycemic Agen

2006
Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
    The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1

    Topics: Acne Vulgaris; Cardiovascular Diseases; Contraceptives, Oral, Combined; Endometrial Neoplasms; Femal

2007
Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review.
    Human reproduction (Oxford, England), 2007, Volume: 22, Issue:5

    Topics: Acne Vulgaris; Adult; Cardiovascular Diseases; Contraceptives, Oral, Combined; Female; Hirsutism; Hu

2007
Polycystic ovary syndrome.
    Best practice & research. Clinical obstetrics & gynaecology, 2008, Volume: 22, Issue:2

    Topics: Acne Vulgaris; Androgen Antagonists; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fem

2008
A systematic review of commonly used medical treatments for hirsutism in women.
    Clinical endocrinology, 2008, Volume: 68, Issue:5

    Topics: Androgen Antagonists; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Drug Therapy, Combination

2008
Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials.
    The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:4

    Topics: Androgen Antagonists; Hirsutism; Humans; Metformin; Randomized Controlled Trials as Topic

2008
Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials.
    The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:4

    Topics: Androgen Antagonists; Drug Therapy, Combination; Hirsutism; Humans; Hypoglycemic Agents; Metformin;

2008
[Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
    Annales d'endocrinologie, 2002, Volume: 63, Issue:1

    Topics: Androgens; Chromans; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing

2002

Trials

21 trials available for metformin and Hirsutism

ArticleYear
Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients.
    Journal of drugs in dermatology : JDD, 2021, 03-01, Volume: 20, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Combined Modality Therapy; Contraceptives, Oral, Combined;

2021
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
    The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2017, Volume: 61, Issue:4

    Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; F

2017
Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.
    European journal of endocrinology, 2017, Volume: 177, Issue:5

    Topics: Adult; Contraceptives, Oral, Combined; Drug Administration Schedule; Female; Hirsutism; Humans; Hypo

2017
Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome.
    European journal of obstetrics, gynecology, and reproductive biology, 2019, Volume: 234

    Topics: Adult; Body Mass Index; Combined Modality Therapy; Exercise Therapy; Female; Glucose Tolerance Test;

2019
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:2

    Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism;

2014
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, Com

2016
Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
    Diabetes & metabolism, 2016, Volume: 42, Issue:3

    Topics: Adolescent; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Fibroblast Growth Fac

2016
Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome.
    Dermatology (Basel, Switzerland), 2009, Volume: 218, Issue:3

    Topics: Adult; Female; Hair Removal; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin;

2009
Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2009, Volume: 107, Issue:3

    Topics: Adult; Clomiphene; Diathermy; Female; Fertility Agents, Female; Hirsutism; Humans; Hypoglycemic Agen

2009
Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2010, Volume: 26, Issue:3

    Topics: Adult; Blood Pressure; Body Mass Index; Cholesterol; Double-Blind Method; Female; Follicle Stimulati

2010
Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:8

    Topics: Adolescent; Child; Female; Follow-Up Studies; Hirsutism; Humans; Hyperandrogenism; Hypoglycemic Agen

2011
Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome.
    European journal of obstetrics, gynecology, and reproductive biology, 2011, Volume: 159, Issue:1

    Topics: Acetylcysteine; Adolescent; Adult; Anticholesteremic Agents; Antioxidants; Body Mass Index; Female;

2011
Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:11

    Topics: Adult; C-Reactive Protein; Drug Therapy, Combination; Female; Hirsutism; Humans; Hydroxymethylglutar

2011
Altering hirsutism through ovulation induction in women with polycystic ovary syndrome.
    Obstetrics and gynecology, 2012, Volume: 119, Issue:6

    Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female;

2012
The effect of metformin on hirsutism in polycystic ovary syndrome.
    European journal of endocrinology, 2002, Volume: 147, Issue:2

    Topics: Body Constitution; Body Height; Body Weight; Double-Blind Method; Female; Hair; Hirsutism; Humans; H

2002
Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2003, Volume: 17, Issue:1

    Topics: Acne Vulgaris; Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Fa

2003
Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.
    The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:9

    Topics: Acne Vulgaris; Androgen Antagonists; Anthropometry; Blood Glucose; Blood Pressure; Body Mass Index;

2003
The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2005, Volume: 21, Issue:3

    Topics: Adult; Androstenedione; Female; Glucose Tolerance Test; Hirsutism; Humans; Hypoglycemic Agents; Insu

2005
Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2007, Volume: 23, Issue:5

    Topics: Adolescent; Adult; Blood Glucose; Body Weight; Female; Hirsutism; Hormones; Humans; Hypoglycemic Age

2007
Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.
    The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:7

    Topics: Androgens; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Body Composition; Cholesterol; Chol

1995
Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
    The Journal of clinical endocrinology and metabolism, 2000, Volume: 85, Issue:10

    Topics: Adolescent; Adult; Blood Glucose; Female; Hirsutism; Hormones; Humans; Hyperandrogenism; Hyperinsuli

2000

Other Studies

24 other studies available for metformin and Hirsutism

ArticleYear
[The 495th case: young female-hyperandrogenemia-severe insulin resistance].
    Zhonghua nei ke za zhi, 2022, Jun-01, Volume: 61, Issue:6

    Topics: Acanthosis Nigricans; Adult; Diabetes Mellitus; Female; Hirsutism; Humans; Insulin; Insulin Resistan

2022
An evaluation of the available pharmacotherapy for the treatment of hirsutism.
    Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:7

    Topics: Androgen Antagonists; Female; Hair; Hirsutism; Humans; Hyperandrogenism; Male; Metformin

2023
Care for Adolescents With Polycystic Ovary Syndrome: Development and Prescribing Patterns of a Multidisciplinary Clinic.
    Journal of pediatric and adolescent gynecology, 2021, Volume: 34, Issue:5

    Topics: Adolescent; Adult; Alopecia; Child; Female; Hirsutism; Humans; Metformin; Polycystic Ovary Syndrome;

2021
[Liraglutide in polycystic ovary syndrome].
    Medicina clinica, 2014, Sep-15, Volume: 143, Issue:6

    Topics: Adult; Diabetes Mellitus, Type 2; Drug Synergism; Female; Glucagon-Like Peptide 1; Hirsutism; Humans

2014
Hyperinsulinaemic androgen excess in adolescent girls.
    Nature reviews. Endocrinology, 2014, Volume: 10, Issue:8

    Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human

2014
European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire.
    European journal of endocrinology, 2014, Volume: 171, Issue:4

    Topics: Adult; Androgens; Biomarkers; Clomiphene; Contraceptives, Oral; Diagnosis, Differential; Endocrinolo

2014
Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome.
    Journal of pediatric and adolescent gynecology, 2014, Volume: 27, Issue:6

    Topics: Adolescent; Blood Glucose; Body Mass Index; Body Weight; Child; Female; Hirsutism; Humans; Hypoglyce

2014
Trends in standard workup performed by pediatric subspecialists for the diagnosis of adolescent polycystic ovary syndrome.
    Journal of pediatric and adolescent gynecology, 2015, Volume: 28, Issue:1

    Topics: Adolescent; Adolescent Medicine; Androgens; Child; Contraceptives, Oral; Endocrinology; Female; Gyne

2015
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015, Volume: 21, Issue:11

    Topics: Adolescent; Alopecia; Androgen Antagonists; Androgens; Anovulation; Diagnostic Techniques, Endocrine

2015
Reply: Metformin for women with hyperandrogenic anovulation.
    Human reproduction update, 2016, Volume: 22, Issue:3

    Topics: Anovulation; Female; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome

2016
Metformin for women with hyperandrogenic anovulation.
    Human reproduction update, 2016, Volume: 22, Issue:3

    Topics: Anovulation; Female; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome

2016
[Woman 19-old with hirsutism, obesity and acanthosis nigricans].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2016, Sep-29, Volume: 41, Issue:243

    Topics: Acanthosis Nigricans; Female; Hirsutism; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Ob

2016
[Polycystic ovary syndrome. Diet helps control hormone chaos].
    MMW Fortschritte der Medizin, 2009, Sep-10, Volume: 151, Issue:37

    Topics: Acne Vulgaris; Adolescent; Adult; Androgens; Child; Combined Modality Therapy; Female; Hirsutism; Hu

2009
Androgen excess in women: not just a cosmetic problem.
    Annales d'endocrinologie, 2010, Volume: 71, Issue:1

    Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Female; Hirsutism; Humans; Hyperan

2010
[Diagnosis and treatment of polycystic ovary syndrome].
    Orvosi hetilap, 2010, Apr-04, Volume: 151, Issue:14

    Topics: Acne Vulgaris; Alopecia; Amenorrhea; Androgens; Clomiphene; Diabetes Complications; Diagnosis, Diffe

2010
[Metformin treatment with or without life style changes in patients with polycystic ovary syndrome].
    Orvosi hetilap, 2011, Apr-17, Volume: 152, Issue:16

    Topics: Acne Vulgaris; Adult; Body Mass Index; Caloric Restriction; Case-Control Studies; Drug Administratio

2011
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012, Volume: 28, Issue:10

    Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem

2012
Hirsutism and adnexal masses in a teenager.
    Journal of pediatric and adolescent gynecology, 2002, Volume: 15, Issue:5

    Topics: Abdominal Pain; Adolescent; Contraceptives, Oral, Combined; Diagnosis, Differential; Female; Hirsuti

2002
[Hirsutism].
    MMW Fortschritte der Medizin, 2003, Aug-07, Volume: 145, Issue:31-32

    Topics: Adolescent; Adrenal Hyperplasia, Congenital; Adult; Androgen Antagonists; Anti-Inflammatory Agents;

2003
The treatment of polycystic ovary syndrome.
    Minerva ginecologica, 2004, Volume: 56, Issue:1

    Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate;

2004
[Treatment experience with metformin in polycystic ovary syndrome].
    Orvosi hetilap, 2005, May-22, Volume: 146, Issue:21

    Topics: Adolescent; Adult; Body Mass Index; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistan

2005
The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
    Journal of endocrinological investigation, 2005, Volume: 28, Issue:11

    Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Fasting; Female; Follicle Stimulating Hormone; Glu

2005
Hirsutism.
    The New England journal of medicine, 2006, Apr-06, Volume: 354, Issue:14

    Topics: Androgen Antagonists; Contraceptives, Oral; Drug Therapy, Combination; Female; Flutamide; Hirsutism;

2006
The use of metformin as first line treatment in polycystic ovary syndrome.
    Irish medical journal, 2008, Volume: 101, Issue:2

    Topics: Adolescent; Adult; Amenorrhea; Body Mass Index; Clomiphene; Female; Follicle Stimulating Hormone; Hi

2008